Havn Life will collaborate on future clinical studies with Heroic Hearts Project to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD).
VANCOUVER, BC / ACCESSWIRE / December 8, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the “Company” or “Havn Life”), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind, is pleased to announce it has signed a Memorandum of Agreement (“MOA”) with the international veterans organization, Heroic Hearts Project (“Heroic Hearts”).
Heroic Hearts is a registered 501(c)(3) non profit organization founded in the United States that connects military veterans struggling with mental trauma, to psychedelic therapy options including ayahuasca, psilocybin, and ketamine. Heroic Hearts also provides support and professional counseling to these veterans throughout the process. These veterans typically have tried all the available resources offered by the Department of Veteran Affairs with limited success leaving them with very few options. Heroic Hearts currently has branches across the United States, Canada, and the United Kingdom.
“This collaboration between Havn Life and Heroic Hearts has the potential to make an extraordinary impact on the mental health and wellness of military veterans,” said Susan Chapelle, EVP of Research and Development at Havn Life. “Under the agreement, Havn Life will supply products and compounds to be used in Heroic Hearts’ future clinical studies that will investigate the effects of low-dosage psychedelic compounds on veterans suffering from emotional trauma and PTSD. This progressive research will help develop clinical trial formulations to aid in the recovery of PTSD and other trauma-related disorders. We look forward to working closely with veterans and others with military backgrounds.”
Heroic Hearts is also working to advance the body of scientific evidence around psychedelic compounds through approved research studies with the University of Georgia and the University of Colorado Boulder. “We are excited to work with a science-focused company like Havn and expand our ability to help Canadian veterans in need. As the only psychedelic therapy advocate for veterans around the world, Heroic Hearts relies on strong relationships with responsible partners to ensure veterans receive the effective care they deserve,” said Jesse Gould, founder of Heroic Hearts Project.
“We are laying the groundwork to lead standardization of the psychedelic supply chain and the development of IP while also contributing to the limited research on PTSD, human performance optimization and cutting-edge mental health paradigms” Chapelle added.
Two-thirds of Canadian military personnel with PTSD do not respond completely to the best available evidence-based therapies, according to a 2018 study that examined recovery, rehabilitation and reintegration of injured service members and veterans. Further, suicide risk is higher in Canadian Armed Forces (CAF) Veterans than the Canadian general population, found a “Life After Service” study published in 2016.
As part of the agreement, Havn Life will supply products for future U.S. and Canadian studies, upon approval of its Licensed Dealer application. Havn Life scientists will provide support for Heroic Heart’s current studies and aid in the development of research protocols. The collaboration will also explore the use of mental health and pharmacology management platforms to collect baseline and usage data from veterans.
Havn Life is also providing funding to launch a Heroic Hearts division in Canada, to help expand support to Canadian Veterans.”
On Behalf of The Board of Directors
Chief Executive Officer
About Havn Life Sciences Inc.
Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.
Investor Relations: [email protected].com 604 687 7130
Media: [email protected] 778 238 6096
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release
SOURCE: Havn Life Sciences Inc.
View source version on accesswire.com: